摘要:
The present invention is based, in part, on our discovery of immunoglobulins (e.g., immunoglobulin G (IgG)) polypeptides (e.g., murine or human IgG, such as human IgG1) that are aglycosylated yet retain the ability to bind to an Fc receptor, such as an activating Fc receptor (e.g., Fcy RIIA and/or FcyRIIIA).
摘要:
The present invention is based, in part, on our discovery of immunoglobulins (e.g., immunoglobulin G (IgG)) polypeptides (e.g., murine or human IgG, such as human IgG1) that are aglycosylated yet retain the ability to bind to an Fc receptor, such as an activating Fc receptor (e.g., FcγRIIA and/or FcγRIIIA).
摘要:
This invention relates to compositions comprising an agent, which inhibits signaling via the FcγRIIB receptor and an agent which stimulates or enhances signaling via an FcγRI receptor, an FcγRIIa receptor, an FcγRIII receptor, or a combination thereof. The invention also provides for the use of such compositions in stimulating or enhancing an immune response, and in treating, suppressing, or preventing cancer in a subject.
摘要:
This invention concerns anti-inflammatory agents and methods for treating inflammatory disorders. Also disclosed are methods for identifying or evaluating anti-inflammatory agents or compositions.